⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for relapse

Every month we try and update this database with for relapse cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation RelapseNCT00083681
Multiple Myelom...
Thalidomide
Dexamethasone
Cytoxan
Etoposide
Cisplatin
G-CSF
18 Years - University of Arkansas
The circTeloDIAG: Liquid Biopsy for Glioma TumorNCT04931732
Glioma
ctDNA analysis
18 Years - 90 YearsHospices Civils de Lyon
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell LymphomaNCT00799513
Diffuse Large B...
Lenalidomide
18 Years - IRCCS San Raffaele
MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCTNCT02673008
Minimal Residua...
Donor Lymphocyt...
Hematopoietic S...
Relapse
donor lymphocyt...
14 Years - 65 YearsNanfang Hospital, Southern Medical University
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaNCT02298348
Neuroblastoma
Sorafenib
Cyclophosphamid...
Topotecan
- 30 YearsNew Approaches to Neuroblastoma Therapy Consortium
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)NCT00368082
Lymphoma
Hodgkin's Disea...
Relapse
Lymphoma, Non-H...
TGFbeta resista...
- Baylor College of Medicine
Picoplatin as Second-Line Therapy for Patients With Small Cell Lung CancerNCT00116610
Small Cell Lung...
picoplatin
18 Years - Poniard Pharmaceuticals
Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System LymphomaNCT05135858
Primary Central...
Glucarpidase
Methotrexate (M...
18 Years - Assistance Publique - Hôpitaux de Paris
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.NCT02017457
Acute Myelogeno...
Myelodysplastic...
Donor lymphocyt...
Azacytidine
18 Years - University Hospital of Mont-Godinne
Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative MalignanciesNCT01385072
Relapsed and Re...
Double matched ...
18 Years - Rabin Medical Center
Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T CellsNCT03236129
Hematological M...
Regulatory T Ce...
Relapse
T-reg depleted ...
Standard DLI
- Assistance Publique - Hôpitaux de Paris
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic MalignanciesNCT03771222
Donor Lymphocyt...
Peripheral Bloo...
Relapse
Graft-versus-ho...
Decitabine
Prophylactic DL...
14 Years - 65 YearsChinese PLA General Hospital
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell LymphomaNCT01606605
Diffuse Large B...
15 Years - 90 YearsSamsung Medical Center
Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse RiskNCT03000335
B-cell Acute Ly...
2 Years - 19 YearsCurewize Health Ltd.
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPNCT02983097
Diffuse Large B...
Follicular Lymp...
Mantle Cell Lym...
Burkitt Lymphom...
Aggressive Marg...
Rituximab
Cisplatin
Carboplatin
Dexamethasone
Cytarabine
Lenalidomide
PegFilgrastim
peripheral stem...
18 Years - 70 YearsGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia PatientsNCT00631059
Leukemia
Hem(A)+ Technol...
18 Years - University of California, Irvine
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's LymphomaNCT05137886
Hodgkin Lymphom...
Relapse
Refractory Hodg...
PD-1 inhibitor
18 Years - 65 YearsInstitute of Hematology & Blood Diseases Hospital, China
Dexamethasone in Refractory or First Relapsed Acute Myeloid LeukemiaNCT03765541
Relapsed or Ref...
Dexamethasone
Amsacrine
Cytarabine
Azacitidine
18 Years - University Hospital, Toulouse
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL AmyloidosisNCT02245867
Amyloidosis
Chimeric Fibril...
21 Years - Columbia University
Gut Mucosal Microbiota is Associated With Colorectal Cancer RelapseNCT03385213
Gut Microbiota
Colorectal Canc...
35 Years - 80 YearsFirst Affiliated Hospital of Harbin Medical University
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)NCT03372057
Peripheral T-ce...
Duvelisib
Duvelisib
Duvelisib
18 Years - SecuraBio
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaNCT03029338
Lymphomas Non-H...
Relapse
CD19 CAR T cell...
18 Years - 70 YearsInstitute of Hematology & Blood Diseases Hospital, China
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDSNCT02204020
Acute Myeloid L...
Myelodysplastic...
5-azacytidine (...
18 Years - University of Pittsburgh
Epigenetic Reprogramming in Relapse/Refractory AMLNCT03263936
Acute Myelogeno...
Decitabine
Vorinostat
Filgrastim (G-C...
Fludarabine
Cytarabine
1 Year - 25 YearsTherapeutic Advances in Childhood Leukemia Consortium
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell LymphomaNCT01606605
Diffuse Large B...
15 Years - 90 YearsSamsung Medical Center
Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma RelapseNCT01794572
Multiple Myelom...
Melphalan
Autologous Hema...
18 Years - 65 YearsInstitut Cancerologie de l'Ouest
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationNCT02631499
Carcinoma, Hepa...
Neoplastic Cell...
TACE
Epirubicin
lipiodol
18 Years - 75 YearsFudan University
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaNCT03029338
Lymphomas Non-H...
Relapse
CD19 CAR T cell...
18 Years - 70 YearsInstitute of Hematology & Blood Diseases Hospital, China
AC220 for Children With Relapsed/Refractory ALL or AMLNCT01411267
Lymphoblastic L...
Myelogenous Leu...
AC220
Cytarabine
Etoposide
Methotrexate
1 Month - 21 YearsTherapeutic Advances in Childhood Leukemia Consortium
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian CarcinomaNCT01481701
Ovarian Carcino...
Relapse
Oxaliplatin
oxaliplatin
18 Years - Jules Bordet Institute
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 CellsNCT06090864
Hodgkin Lymphom...
Relapse
Refractory
Chemotherapy
Cell infusion
18 Years - UNC Lineberger Comprehensive Cancer Center
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseNCT00335348
Multiple Myelom...
Bortezomib
Dexamethasone
18 Years - 80 YearsPeter MacCallum Cancer Centre, Australia
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsNCT05537740
Advanced Solid ...
BAY3375968
Pembrolizumab
18 Years - Bayer
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple MyelomaNCT01470131
Multiple Myelom...
Masitinib
Placebo
Bortezomib
Dexamethasone
18 Years - AB Science
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T CellsNCT06347068
Breast Cancer
Relapse
Resistant Cance...
Triple Negative...
iC9-CAR.B7-H3 T...
cyclophosphamid...
fludarabine
18 Years - UNC Lineberger Comprehensive Cancer Center
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor MalignancyNCT00230217
Tumors
Hyperuricemia
Tumor Lysis Syn...
Rasburicase (SR...
- Sanofi
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)NCT01186328
Lymphoblastic L...
Lymphoblastic L...
Leukemia, Lymph...
Leukemia, Lymph...
EZN-3042
Cytarabine
Doxorubicin
Prednisone
Vincristine
PEG-asparaginas...
Methotrexate
Hydrocortisone
1 Year - 21 YearsTherapeutic Advances in Childhood Leukemia Consortium
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT01310101
Chronic Lymphoc...
ofatumumab plus...
18 Years - Brno University Hospital
ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic LeukemiaNCT00114348
Lymphoblastic L...
Lymphoma, Non-H...
R-Blocks
Protocol II-Ida
- 18 YearsCharite University, Berlin, Germany
Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic LeukaemiaNCT00723346
Acute Lymphobla...
GRASPA
GRASPA
GRASPA
native L aspara...
1 Year - 55 YearsERYtech Pharma
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic MalignanciesNCT02145403
Hematologic Mal...
Relapse
Graft-Versus-Ho...
Carfilzomib
Tacrolimus
18 Years - 70 YearsUniversity of Michigan Rogel Cancer Center
CTL019 Out of Specification MAP for ALL or DLBCL PatientsNCT03601442
Acute Lymphobla...
Diffuse Large B...
CTL019
1 Day - 25 YearsNovartis
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT01310101
Chronic Lymphoc...
ofatumumab plus...
18 Years - Brno University Hospital
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AMLNCT00363974
Leukemia, Myelo...
XIAP antisense
18 Years - Aegera Therapeutics
Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic CancerNCT02948309
Pancreatic Canc...
Mistletoe extra...
Placebo
18 Years - Karolinska University Hospital
Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal CancerNCT00888810
Cancer
Ovarian
Relapse
Chemotherapy
TOPOTECAN
LAPATINIB
18 Years - Centre Francois Baclesse
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) LeukemiaNCT00167167
Leukemia, Myelo...
AML
MDS
Leukemia, Lymph...
Donor Lymphocyt...
1 Year - 60 YearsMasonic Cancer Center, University of Minnesota
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaNCT03029338
Lymphomas Non-H...
Relapse
CD19 CAR T cell...
18 Years - 70 YearsInstitute of Hematology & Blood Diseases Hospital, China
STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational StudyNCT05455736
Prostate Cancer
Relapse
Stereotactic sa...
18 Years - Azienda Ospedaliero-Universitaria Careggi
Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLLNCT01612988
B-cell Chronic ...
BOMP
18 Years - 80 YearsFrench Innovative Leukemia Organisation
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for MyelosuppressionNCT00482261
Multiple Myelom...
Lenalidomide
dexamethasone
aspirin
18 Years - Peter MacCallum Cancer Centre, Australia
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)NCT00822094
Acute Myeloid L...
CPX-351
Intensive Salva...
18 Years - 65 YearsJazz Pharmaceuticals
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple MyelomaNCT03697629
Multiple Myelom...
Daratumumab
18 Years - Canadian Myeloma Research Group
Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid CarcinomaNCT02515084
Thyroid Cancer
Relapse
PET
MRI imaging
18 Years - Centre Henri Becquerel
Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)NCT02163720
Ovarian Cancer
Yondelis®-Caely...
18 Years - ARCAGY/ GINECO GROUP
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)NCT03372057
Peripheral T-ce...
Duvelisib
Duvelisib
Duvelisib
18 Years - SecuraBio
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic LeukemiaNCT04723901
Dual-target CAR...
B ALL
Relapse
Refractory B Ac...
Dual target CAR...
14 Years - 75 YearsShenzhen University General Hospital
MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCTNCT02673008
Minimal Residua...
Donor Lymphocyt...
Hematopoietic S...
Relapse
donor lymphocyt...
14 Years - 65 YearsNanfang Hospital, Southern Medical University
Dexamethasone in Refractory or First Relapsed Acute Myeloid LeukemiaNCT03765541
Relapsed or Ref...
Dexamethasone
Amsacrine
Cytarabine
Azacitidine
18 Years - University Hospital, Toulouse
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaNCT01889420
Multiple Myelom...
Combination the...
18 Years - New Mexico Cancer Care Alliance
A Study Of Panobinostat In Children With Refractory Hematologic MalignanciesNCT01321346
Lymphoblastic L...
Myelogenous Leu...
Hodgkin's Disea...
Non-Hodgkin's L...
Panobinostat
Cytarabine
Panobinostat
8 Years - 21 YearsTherapeutic Advances in Childhood Leukemia Consortium
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell LymphomasNCT01788189
B-cell Lymphoma
Lenalidomide
18 Years - University Hospital, Essen
Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid CarcinomaNCT02515084
Thyroid Cancer
Relapse
PET
MRI imaging
18 Years - Centre Henri Becquerel
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationNCT03560908
Relapsed AML
T(8;21)
C-KIT Mutation
Dasatinib
- Institute of Hematology & Blood Diseases Hospital, China
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell TransplantationNCT00984165
Hodgkin's Lymph...
Non-Hodgkin's L...
Chronic Lymphoc...
Multiple Myelom...
Single fraction...
Donor Lymphocyt...
Apheresis
18 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRDNCT05137860
Acute Lymphobla...
Chemotherapeuti...
Minimal Residua...
Bortezomib
18 Years - 50 YearsHospital General de Mexico
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)NCT02846038
Brain Tumors
Solid Tumor
- St. Jude Children's Research Hospital
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and AdolescentsNCT01517776
Gliomas
Cilengitide
Temozolomide
3 Years - 17 YearsMartin-Luther-Universität Halle-Wittenberg
Treatment of Acute Leukemia Relapse After AllotransplantationNCT01369368
Acute Myeloid L...
Combined use of...
18 Years - 90 YearsUniversity of Bergen
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibNCT02140840
Multiple Myelom...
Trametinib
18 Years - University of Arkansas
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute LeukemiaNCT04674345
Acute Leukemia
Relapse
Hematopoietic S...
Sorafenib
18 Years - 65 YearsNanfang Hospital, Southern Medical University
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL AmyloidosisNCT02245867
Amyloidosis
Chimeric Fibril...
21 Years - Columbia University
Interferon-α Prevents Leukemia Relapse of AML Patients After TransplantationNCT03121079
Interferon-A-2B
Relapse
Prevention
Hematopietic St...
Interferon-alph...
18 Years - 60 YearsPeking University People's Hospital
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic MalignanciesNCT03771222
Donor Lymphocyt...
Peripheral Bloo...
Relapse
Graft-versus-ho...
Decitabine
Prophylactic DL...
14 Years - 65 YearsChinese PLA General Hospital
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation RelapseNCT00083681
Multiple Myelom...
Thalidomide
Dexamethasone
Cytoxan
Etoposide
Cisplatin
G-CSF
18 Years - University of Arkansas
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationNCT03560908
Relapsed AML
T(8;21)
C-KIT Mutation
Dasatinib
- Institute of Hematology & Blood Diseases Hospital, China
Smoking Relapse-Prevention Intervention for Cancer PatientsNCT01630161
Smoking Cessati...
Usual Care
Smoking Relapse...
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple MyelomaNCT00306813
Relapse
Refractory Mult...
Revlimid
18 Years - University of Wuerzburg
Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell TransplantationNCT05250362
Hematologic Mal...
Allogeneic Hema...
18 Years - 60 YearsSichuan University
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid LeukemiaNCT00233909
Leukemia, Myelo...
Zosuquidar
gemtuzumab ozog...
18 Years - Kanisa Pharmaceuticals
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: